Visceral obesity, the metabolic syndrome, androgens and estrogens

Reference List

• Roemmich J N, Clark P A, Mai V, Berr S S, Weltman A, Veldhuis J D, Rogol A D. Alterations in growth and body composition during puberty: III. Influence of maturation, gender, body composition, fat distribution, aerobic fitness, and energy expenditure on nocturnal growth hormone release. J Clin Endocrinol Metab 1998; 83(5)1440–1447
   PubMed Web of Science ®Google Scholar
• Seidell J C, Bjorntorp P, Sjostrom L, Kvist H, Sannerstedt R. Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism 1990; 39(9)897–901
   PubMed Web of Science ®Google Scholar
• Khaw K T, Barrett-Connor E. Lower endogenous androgens predict central adiposity in men. Ann Epidemiol 1992; 2(5)675–682
   PubMedGoogle Scholar
• Despres J P, Couillard C, Gagnon J, Bergeron J, Leon A S, Rao D C, Skinner J S, Wilmore J H, Bouchard C. Race, visceral adipose tissue, plasma lipids, and lipoprotein lipase activity in men and women: the Health, Risk Factors, Exercise Training, and Genetics (HERITAGE) family study. Arterioscler Thromb Vasc Biol 2000; 20(8)1932–1938
   PubMed Web of Science ®Google Scholar
• Tchernof A, Labrie F, Belanger A, Prud'homme D, Bouchard C, Tremblay A, Nadeau A, Despres J P. Relationships between endogenous steroid hormone, sex hormone-binding globulin and lipoprotein levels in men: contribution of visceral obesity, insulin levels and other metabolic variables. Atherosclerosis 1997; 133(2)235–244
   PubMed Web of Science ®Google Scholar
• Kaufman J M, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocrin Rev 2005; 26: 833–876
   PubMed Web of Science ®Google Scholar
• Simon D, Charles M A, Nahoul K, Orssaud G, Kremski J, Hully V, Joubert E, Papoz E, Eschwege E. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The Telecom Study. J Clin Endocrinol Metab 1997; 82(2)682–685
   PubMed Web of Science ®Google Scholar
• Pitteloud N, Mootha V K, Dwyer A A, Hardin M, Lee H, Eriksson K F, Tripathy D, Yialamas M, Groop L, Elahi D, Hayes F J. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 2005; 28(7)1636–1642
   PubMed Web of Science ®Google Scholar
• Blouin K, Despres J P, Couillard C, Tremblay A, Prud'homme D, Bouchard C, Tchernof A. Contribution of age and declining androgen levels to features of the metabolic syndrome in men. Metabolism 2005; 54(8)1034–1040
   PubMed Web of Science ®Google Scholar
• Stellato R K, Feldman H A, Hamdy O, Horton E S, McKinlay J B. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care 2000; 23(4)490–494
   PubMed Web of Science ®Google Scholar
• Vgontzas A N, Papanicolaou D A, Bixler E O, Hopper K, Lotsikas A, Lin H M, Kales A, Chronsos G P. Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. J Clin Endocrinol Metab 2000; 85(3)1151–1158
   PubMed Web of Science ®Google Scholar
• Katznelson L, Rosenthal D I, Rosol M S, Anderson E J, Hayden D L, Schoenfeld D A, Klibanski A. Using quantitative CT to assess adipose distribution in adult men with acquired hypogonadism. AJR Am J Roentgenol 1998; 170(2)423–427
   PubMed Web of Science ®Google Scholar
• Mauras N, Hayes V, Welch S, Rini A, Helgeson K, Dokler M, Veldhuis J D, Urban R J. Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity. J Clin Endocrinol Metab 1998; 83(6)1886–1892
   PubMed Web of Science ®Google Scholar
• Pritchard J, Despres J P, Gagnon J, Tchernof A, Nadeau A, Tremblay A, Bouchard C. Plasma adrenal, gonadal, and conjugated steroids before and after long-term overfeeding in identical twins. J Clin Endocrinol Metab 1998; 83(9)3277–3284
   PubMed Web of Science ®Google Scholar
• Tchernof A, Labrie F, Belanger A, Prud'homme D, Bouchard C, Tremblay A, Nadeau A, Despres J P. Androstane-3alpha,17-beta-diol glucuronide as a steroid correlate of visceral obesity in men. J Clin Endocrinol Metab 1997; 82(5)1528–1534
   PubMed Web of Science ®Google Scholar
• Vermeulen A, Kaufman J M, Giagulli V A. Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males. J Clin Endocrinol Metab 1996; 81(5)1821–1826
   PubMed Web of Science ®Google Scholar
• Leenen R, van der Kooy K, Seidell J C, Deurenberg P, Koppeschaar H P. Visceral fat accumulation in relation to sex hormones in obese men and women undergoing weight loss therapy. J Clin Endocrinol Metab 1994; 78(6)1515–1520
   PubMed Web of Science ®Google Scholar
• Zmuda J M, Cauley J A, Kriska A, Glynn N W, Gutai J P, Kuller L H. Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men. A 13-year follow-up of former Multiple Risk Factor Intervention Trial participants. Am J Epidemiol 1997; 146(8)609–617
   PubMed Web of Science ®Google Scholar
• Tsai E C, Boyko E J, Leonetti D L, Fujimoto W Y. Low serum testosterone level as a predictor of increased visceral fat in Japanese–American men. Int J Obes Relat Metab Disord 2000; 24(4)485–491
   PubMed Web of Science ®Google Scholar
• Rosmond R, Wallerius S, Wanger P, Martin L, Holm G, Bjorntorp P. A 5-year follow-up study of disease incidence in men with an abnormal hormone pattern. J Intern Med 2003; 254(4)386–390
   PubMed Web of Science ®Google Scholar
• Marin P, Arver S. Androgens and abdominal obesity. Baillieres Clin Endocrinol Metab 1998; 12(3)441–451
   PubMedGoogle Scholar
• Tchernof A, Poehlman E T. Effects of the menopause transition on body fatness and body fat distribution. Obes Res 1998; 6(3)246–254
   PubMedGoogle Scholar
• Liu P Y, Death A K, Handelsman D J. Androgens and cardiovascular disease. Endocr Rev 2003; 24(3)313–340
   PubMed Web of Science ®Google Scholar
• Wu F C, von Eckardstein A. Androgens and coronary artery disease. Endocr Rev 2003; 24(2)183–217
   PubMed Web of Science ®Google Scholar
• Brodsky I G, Balagopal P, Nair K S. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men – a clinical research center study. J Clin Endocrinol Metab 1996; 81(10)3469–3475
   PubMed Web of Science ®Google Scholar
• Snyder P J, Peachey H, Berlin J A, Hannoush P, Haddad G, Dlewati A, Santanna J, Loh L, Lenrow D A, Holmes J H, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000; 85(8)2670–2677
   PubMed Web of Science ®Google Scholar
• Dobs A S, Bachorik P S, Arver S, Meikle A W, Sanders S W, Caramelli K E, Mazer N A. Interrelationships among lipoprotein levels, sex hormones, anthropometric parameters, and age in hypogonadal men treated for 1 year with a permeation-enhanced testosterone transdermal system. J Clin Endocrinol Metab 2001; 86(3)1026–1033
   PubMed Web of Science ®Google Scholar
• Schroeder E T, Zheng L, Ong M D, Martinez C, Flores C, Stewart Y, Azen C, Sattler F R. Effects of androgen therapy on adipose tissue and metabolism in older men. J Clin Endocrinol Metab 2004; 89(10)4863–4872
   PubMed Web of Science ®Google Scholar
• Bhasin S, Storer T W, Berman N, Yarasheski K E, Clevenger B, Phillips J, Lee W P, Bunnell T S, Casaburi R. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 1997; 82(2)407–413
   PubMed Web of Science ®Google Scholar
• Wang C, Eyre D R, Clark R, Kleinberg D, Newman C, Iranmanesh A, Veldhuis J, Dudley R E, Berman N, Davidson T, et al. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men – a clinical research center study. J Clin Endocrinol Metab 1996; 81(10)3654–3662
   PubMed Web of Science ®Google Scholar
• Rebuffe-Scrive M, Marin P, Bjorntorp P. Effect of testosterone on abdominal adipose tissue in men. Int J Obes 1991; 15(11)791–795
   PubMed Web of Science ®Google Scholar
• Snyder P J, Peachey H, Hannoush P, Berlin J A, Loh L, Lenrow D A, Holmes J H, Dlewati A, Santanna J, Rosen C J, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 1999; 84(8)2647–2653
   PubMed Web of Science ®Google Scholar
• Rolf C, von Eckardstein S, Koken U, Nieschlag E. Testosterone substitution of hypogonadal men prevents the age-dependent increases in body mass index, body fat and leptin seen in healthy ageing men: results of a cross-sectional study. Eur J Endocrinol 2002; 146(4)505–511
   PubMed Web of Science ®Google Scholar
• Marin P, Oden B, Bjorntorp P. Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: effects of androgens. J Clin Endocrinol Metab 1995; 80(1)239–243
   PubMed Web of Science ®Google Scholar
• Woodhouse L J, Gupta N, Bhasin M, Singh A B, Ross R, Phillips J, Bhasin S. Dose-dependent effects of testosterone on regional adipose tissue distribution in healthy young men. J Clin Endocrinol Metab 2004; 89(2)718–726
   PubMed Web of Science ®Google Scholar
• Knowler W C, Barrett-Connor E, Fowler S E, Hamman R F, Lachin J M, Walker E A, Nathan D M. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346(6)393–403
   PubMed Web of Science ®Google Scholar
• Liu P Y, Wishart S M, Celermajer D S, Jimenez M, Pierro I D, Conway A J, Handelsman D J. Do reproductive hormones modify insulin sensitivity and metabolism in older men? A randomized, placebo-controlled clinical trial of recombinant human chorionic gonadotropin. Eur J Endocrinol 2003; 148(1)55–66
   PubMed Web of Science ®Google Scholar
• Makhsida N, Shah J, Yan G, Fisch H, Shabsigh R. Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol 2005; 174(3)827–834
   PubMed Web of Science ®Google Scholar
• Kapoor D, Malkin C J, Channer K S, Jones T H. Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf) 2005; 63(3)239–250
   PubMed Web of Science ®Google Scholar
• Vermeulen A, Kaufman J M, Goemaere S, van Pottelberg I. Estradiol in elderly men. Aging Male 2002; 5(2)98–102
   PubMedGoogle Scholar
• Rochira V, Granata A R, Madeo B, Zirilli L, Rossi G, Carani C. Estrogens in males: what have we learned in the last 10 years?. Asian J Androl 2005; 7(1)3–20
   PubMed Web of Science ®Google Scholar
• Phillips G B. Is atherosclerotic cardiovascular disease an endocrinological disorder? The estrogen-androgen paradox. J Clin Endocrinol Metab 2005; 90(5)2708–2711
   PubMed Web of Science ®Google Scholar
• Shearman A M, Cupples L A, Demissie S, Peter I, Schmid C H, Karas R H, Mendelsohn M E, Housman D E, Levy D. Association between estrogen receptor alpha gene variation and cardiovascular disease. JAMA 2003; 290(17)2263–2270
   PubMed Web of Science ®Google Scholar
• Panet-Raymond V, Gottlieb B, Beitel L K, Pinsky L, Trifiro M A. Interactions between androgen and estrogen receptors and the effects on their transactivational properties. Mol Cell Endocrinol 2000; 167(1–2)139–150
   PubMed Web of Science ®Google Scholar